Effect of Metformin (Drug)in Patients With Cryptogenic Cirrhosis (Liver Disease) With Diabetes
- Conditions
- Health Condition 1: null- Cryptogenic cirrhosis with DiabetesHealth Condition 2: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2018/03/012814
- Lead Sponsor
- Institute of liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 86
1)Age 18 years and above
2)Patients with cryptogenic cirrhosis {NASH (Nash Alcoholic Steatohepatitis)-related cirrhosis}
3)Presence of diabetes mellitus or insulin resistance
1)Patients with heart failure
2)Patients with acute kidney injury at the time of enrollment
3)Patients with CKD (Chronic Kidney Disease) or with S. Creatinine > 1 mg/dL
4)Patient with active upper GI bleeding- not settled
5)Patient with SIRS/sepsis/shock
6)Patient in ICU (Intensive Care Unit)
7)Pregnancy
8)Patients with hepatocellular carcinoma
9)Patients who are not willing to participate in the study
10)Patients with any form of decompensation at the time of enrollment in the study
11)Patient with large esophageal varices/ patients who are on beta blocker other than those patients with HVPG (Hepatic Venous Pressure Gradient) non responder to betablocker
12)Patient who has already been receiving Metformin prior to enrollment in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of portal pressureTimepoint: 1 Year
- Secondary Outcome Measures
Name Time Method Improvement in fibrosis(assessed by noninvasive methods like Fibroscan and Fib 4 index)Timepoint: 1 year;Safety profile of the drugs like Random Blood Sugar (RBS) and serum lactate monitoring regularly.Timepoint: 1.5 years